New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases

PHASE3CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Colorectal NeoplasmsNeoplasm MetastasisLiver NeoplasmsChemotherapy; Maternal, Affecting Fetus
Interventions
DRUG

chemotherapy ± targeted therapy

Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.

Trial Locations (1)

200032

Zhongshan hospital, Fudan university, Shanghai

All Listed Sponsors
collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

Changhai Hospital

OTHER

lead

Fudan University

OTHER

NCT01307878 - New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases | Biotech Hunter | Biotech Hunter